(NASDAQ: GANX) Gain Therapeutics's forecast annual revenue growth rate of 49.67% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.23%.
Gain Therapeutics's revenue in 2024 is $55,180.On average, 3 Wall Street analysts forecast GANX's revenue for 2024 to be $8,109,855, with the lowest GANX revenue forecast at $2,757,351, and the highest GANX revenue forecast at $16,219,709. On average, 2 Wall Street analysts forecast GANX's revenue for 2025 to be $4,703,716, with the lowest GANX revenue forecast at $2,919,548, and the highest GANX revenue forecast at $6,487,884.
In 2026, GANX is forecast to generate $3,730,533 in revenue, with the lowest revenue forecast at $3,730,533 and the highest revenue forecast at $3,730,533.